Acorda Drops Epilepsy Candidate Once Central To Its Revenue Forecasts
This article was originally published in The Pink Sheet Daily
Plumiaz, a nasal spray formulation of diazepam, is discontinued after it fails one of three Phase III trials undertaken to comply with 2014 FDA complete response letter.
You may also be interested in...
Acorda Therapeutics highlighted the other indications it has in the works for its MS drug Ampyra, as well as several early-stage compounds in other neurological indications.
In this week's podcast edition of Five Must-Know Things: safety debate as more lecanemab data reported; amyloid discussions continue at Alzheimer’s meeting; China COVID unrest affect country’s biotech sector; and Merck’s CMO talks about post-Keytruda plans.
Demand-related shortages are a relatively new problem, but the FDA maintains their tools can prevent or end them.